Scilex Holding

SCLX

Market cap $57.7M

Datavault AI signed $49M of Tokenization and Technology Licensing agreements in Q4'25 that impact FY2025 and FY2026 Revenue. Revenue: Datavault AI expects at least $30 million in revenue for FY2025, compared to $2.7 million in FY2024.

PALO ALTO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that it has made a $20 million strategic investment in Quantum Scan Holdings, Inc. (“Quantum Scan”), a breakthrough medical technology company, targeting trillion-dollar market of preventive diagnosis and prognosis of human diseases and illness.

PALO ALTO, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, announced that it has appointed Kasowitz LLP and its founding partner Marc Kasowitz as the Company's litigation and intellectual property counsel.

PALO ALTO, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, announced confirmed Dream Bowl 2026 Meme Coins claim process on December 24, 2025.

PALO ALTO, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, announced today that it has closed the second tranche of its strategic investment in Datavault AI in BTC (based on the spot exchange rate of BTC as of the signing of the strategic investment). The closing of this second tranche followed the approval by the Datavault stockholders at Datavault's November 24, 2025 annual meeting of the issuance of the shares of Datavault common stock upon exercise of the pre-funded warrant. Scilex's shares of Datavault common stock issued upon the exercise in full of the pre-funded warrant have an approximate value of $583.3 million based on the closing price of $2.21 per share of Datavault AI common stock on the Nasdaq Capital Market on November 25, 2025.

PALO ALTO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, announced today the closing of its previously announced exercise of certain existing warrants to purchase an aggregate of (i) 428,572 shares of common stock (the “Common Stock”) having an exercise of $38.50 per share and issued in April 2024 (the “April 2024 Warrants”) and (ii) 475,824 shares of Common Stock having an exercise price of $22.72 per share and issued in December 2024 (together with the April 2024 Warrants, the “Existing Warrants”) at a reduced exercise price of $22.51 per share. The aggregate gross proceeds from the exercise of the Existing Warrants were approximately $20.3 million, before deducting placement agent fees and other offering expenses payable by the Company.

PALO ALTO, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, announced today that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of (i) 428,572 shares of common stock (the “Common Stock”) having an exercise of $38.50 per share and issued in April 2024 (the “April 2024 Warrants”) and (ii) 475,824 shares of Common Stock having an exercise price of $22.72 per share and issued in December 2024 (together with the April 2024 Warrants, the “Existing Warrants”).

PALO ALTO, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, announced today that, with respect to the voluntary distribution by Datavault AI Inc. (“Datavault AI”) (Nasdaq: DVLT) of Dream Bowl 2026 Meme Coins to record holders of Scilex common stock, given that such distribution is being made by Datavault AI as a token of its appreciation for Scilex's relationship with Datavault AI as a stockholder of Datavault AI, licensing partner and co-sponsor of the Dream Bowl XIV event to be held on January 11, 2026, Nasdaq has informed Datavault AI that it is not planning to make any announcement for Scilex regarding such distribution, whether as to the record date or an ex-dividend date. Notwithstanding the absence of such announcement, Datavault AI has informed the Company that it intends to make such voluntary distribution to record holders of Scilex common stock as of November 25, 2025 concurrently with the distribution of the Dream Bowl 2026 Meme Coins to Datavault AI's eligible record equity holders, including the Company.

PALO ALTO, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that the Board of Directors of Datavault AI Inc. (“Datavault AI”) (Nasdaq: DVLT) has approved the distribution of a Dream Bowl 2026 Meme Coin to all [eligible] Scilex and Datavault AI stockholders of record and set a record date of November 25, 2025 for determining stockholders entitled to receive the Dream Bowl 2026 Meme Coin from Datavault AI.

PHILADELPHIA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- via IBN – Datavault AI Inc. (NASDAQ: DVLT), a leader in data monetization, credentialing, and digital engagement technologies, today released an Investor Update detailing key developments across its financial performance, technology platforms, and international footprint as the company continues to expand its presence in the global proof economy. Datavault's recent progress reflects its commitment to creating measurable shareholder value through innovation, partnerships, and verified growth.